Halozyme Therapeutics market cap HALO
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $14.6B
- Highest close in our data
- $14.9B
- Oct 2026
Halozyme Therapeutics is worth $14.6B at the close on Nov 2, 2026, at $128.95 a share.
That is up 82% over the last year and up 155% over five years.
Its highest close in our data was $14.9B in Oct 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $14.6B | $7.3B | $14.9B | +81% |
| 2025 | $8.1B | $6.1B | $9.1B | +32% |
| 2024 | $6.1B | $4.4B | $8.1B | +25% |
| 2023 | $4.9B | $4.2B | $7.5B | −37% |
| 2022 | $7.7B | $4.6B | $8B | +36% |
| 2021 | $5.7B | $4.6B | $6.8B | −2% |
| 2020 | $5.8B | $2.2B | $5.8B | +119% |
| 2019 | $2.6B | $2.1B | $2.8B | +28% |
| 2018 | $2.1B | $2B | $3B | −28% |
| 2017 | $2.9B | $1.5B | $2.9B | +125% |
| 2016 | $1.3B | $965.2M | $1.9B | −42% |
| 2015 | $2.2B | $182.5M | $3.1B | +84% |
| 2014 | $1.2B | $894.1M | $1.9B | −31% |
| 2013 | $1.7B | $583.7M | $1.7B | +132% |
| 2012 | $749.5M | $518.4M | $1.4B | −24% |
| 2011 | $986.1M | $631M | $1B | n/a |
Against its peers
Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| HALOHalozyme Therapeutics | $14.6B |
| NBIXNeurocrine Biosciences | $14.8B |
| EXELExelixis | $17.4B |
| TECHBIO-TECHNE | $11.4B |
| ALNYAlnylam Pharmaceuticals | $21.2B |
| RGENRepligen | $9.8B |
| INCYIncyte | $24.3B |
| KRYSKrystal Biotech | $8.8B |
| UTHRUnited Therapeutics | $25.9B |
| ONCBeOne Medicines | $40.2B |
| ADMAAdma Biologics | $2.5B |
| Peer median | $16.1B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Halozyme Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.